TABLE 1.

Clinicopathologic Findings Among B-MCL, P-MCL, and Hybrid MCL

	Blastoid	Pleomorphic	Hybrid	P (blastoid vs. pleomorphic)	P (blastoid vs. hybrid)	P (pleomorphic vs. hybrid)
Clinical features
Patients	32	53	17	NA	NA
Sex				0.435	0.217	0.463
Male	65.6	73.6	82.4
Female	34.4	26.4	17.6
Age (median) (y)	59.5	62	62	0.55	0.614	0.666
Stage				0.657	0.662	0.93
Limited (I/II)	3.5	5.7	6.3
Advanced (III/IV)	96.5	94.3	93.7
Treatment response				0.035	0.609	0.011
CR/PR	76	93.5	68.7
Refractory	24	6.5	31.3
Relapse rate (%)	45.8	40	50	0.64	0.796	0.487
Pathologic features
Mitotic figures/10 HPF	52.5	42	63	0.532	0.066	0.011
Starry-sky appearance (%)	50	32.7	52.9	0.115	0.845	0.135
Nucleolus (%)	17.2	13.3	20	0.645	0.845	0.589
Ki-67 proliferation rate (%)	60	40	70	0.003	0.922	0.013
p53 overexpression (%)	38.5	34.4	37.5	0.795	0.965	0.868
SOX11 expression (%)	100	100	90	NA	0.305	0.09
CD5 expression (%)	93.8	98.1	94.1	0.299	0.959	0.398
CD10 expression (%)	0	10.2	7.7	0.12	0.187	0.786
BCL6 expression (%)	25	14.3	60	0.495	0.207	0.029
EZH2 high (%)	56.3	61.5	88	0.735	0.126	0.17
Complex karyotype (%)	66.6	100	NA	0.212	NA	NA

Bold values are statistically significant p<0.05.

EZH2 high indicates ≥40% of lymphoma cells express EZH2; NA, not available.